Natural History of Phenotypic Changes in Stargardt Macular Dystrophy

Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612-7234, USA.
Ophthalmic Genetics (Impact Factor: 1.23). 07/2009; 30(2):63-8. DOI: 10.1080/13816810802695550
Source: PubMed

ABSTRACT Stargardt macular dystrophy is the most common form of juvenile onset macular degeneration. This article reviews the four stages through which this dystrophy may progress. Also, reviewed here are the variations that may be observed in the visual acuity of patients with Stargardt disease.

  • Source
    • "Stargardt disease (STGD: OMIM #248200/#600110) is an inherited genetic eye disease in which patients develop bilateral macular dystrophy leading to progressive loss of central vision in early childhood. It is the most common form of autosomal recessive juvenile macular dystrophy with a reported prevalence of 1 : 10000 [1] [2]. The disease is characterized by loss of central vision, fundus flavimaculatus, mottling or atrophy of the retinal pigment epithelium (RPE), bull's eye maculopathy, flecks in the macula, beaten-bronze macular appearance, and cone-rod dysfunction [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stargardt disease (STGD) is the leading cause of juvenile macular degeneration associated with progressive central vision loss, photophobia, and colour vision abnormalities. In this study, we have described the clinical and genetic features of Stargardt patients from an Indian cohort. The next generation sequencing was carried out in five clinically confirmed unrelated patients and their family members using a gene panel comprising 184 retinal specific genes. Sequencing results were analyzed by read mapping and variant calling in genes of interest, followed by their verification and interpretation. Genetic analysis revealed ABCA4 mutations in all of the five unrelated patients. Among these, four patients were found with compound heterozygous mutations and another one had homozygous mutation. All the affected individuals showed signs and symptoms consistent with the disease phenotype. We report two novel ABCA4 mutations in Indian patients with STGD disease, which expands the existing spectrum of disease-causing variants and the understanding of phenotypic and genotypic correlations. Screening for causative mutations in patients with STGD using panel of targeted gene sequencing by NGS would be a cost effective tool, might be helpful in confirming the precise diagnosis, and contributes towards the genetic counselling of asymptomatic carriers and isolated patients.
    01/2015; 2015:1-10. DOI:10.1155/2015/940864
  • Source
    • "Photoreceptor loss also occurs due, in part, to the inability of the degenerated RPE to phagocytose the photoreceptor outer segments, as illustrated by the lack of phagosomes (Ph) within the RPE cells. phagocytosis (Walia and Fishman, 2009). The most common form of the disease is STGD1, which is autosomal recessive. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cell therapy for retinal disease is under way, and several clinical trials are currently recruiting. These trials use human embryonic, foetal and umbilical cord tissue-derived stem cells and bone marrow-derived stem cells to treat visual disorders such as age-related macular degeneration, Stargardt's disease and retinitis pigmentosa. Over a decade of analysing the developmental cues involved in retinal generation and stem cell biology, coupled with extensive surgical research, have yielded differing cellular approaches to tackle these retinopathies. Here, we review these various stem cell-based approaches for treating retinal diseases and discuss future directions and challenges for the field.
    Development 06/2013; 140(12):2576-2585. DOI:10.1242/dev.092270 · 6.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Retinal dystrophies are inherited disorders of photoreceptor and retinal pigment epithelial function that may result in severe visual impairment. Advances in molecular genetics have helped identify many of the gene defects responsible, and progress in gene transfer technology has enabled therapeutic strategies to be developed and applied. The first human clinical trials of gene therapy for RPE65 associated retinal dystrophy have shown promising initial results and have helped prepare the way for further trials of gene therapy for inherited retinal disorders. The results of these trials will provide further insight into the safety and efficacy of gene therapy for a range of currently untreatable and debilitating eye disorders.
    European Journal of Pediatrics 05/2011; 171(5). DOI:10.1007/s00431-011-1615-2 · 1.98 Impact Factor
Show more